SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Moonlake Immunotherapeutics operates as a clinical-stage biotechnology company. It offers tri-specific Nanobody, Sonelokimab to address significant unmet needs in inflammatory skin and joint diseases. The company was founded by Kristian Reich, Jorge Santos da Silva, and Arnout Ploos van Amstel in 2021 and is headquartered in Zug, Switzerland.

MoonLake Immunotherapeutics - Ordinary Shares - Class A

MoonLake Immunotherapeutics

MoonLake Immunotherapeutics is trending after receiving positive FDA feedback, confirming that existing clinical trial data for its lead candidate, sonelokimab, is sufficient for a Biologics License Application in hidradenitis suppurativa. This regulatory clarity has significantly de-risked the asset, fueling intense community discussion about potential buyout offers and the stock's substantial undervaluation compared to previous bids from major pharmaceutical companies.

Apple, Inc. engages in the design, manufacture, and sale of smartphones, personal computers, tablets, wearables and accessories, and other varieties of related services. It operates through the following geographical segments: Americas, Europe, Greater China, Japan, and Rest of Asia Pacific. The Americas segment includes North and South America. The Europe segment consists of European countries, as well as India, the Middle East, and Africa. The Greater China segment comprises China, Hong Kong, and Taiwan. The Rest of Asia Pacific segment includes Australia and Asian countries. Its products and services include iPhone, Mac, iPad, AirPods, Apple TV, Apple Watch, Beats products, AppleCare, iCloud, digital content stores, streaming, and licensing services. The company was founded by Steven Paul Jobs, Ronald Gerald Wayne, and Stephen G. Wozniak in April 1976 and is headquartered in Cupertino, CA.

Apple Inc

Apple is trending as its stock experiences a notable downturn, prompting community discussion about its "oversold" status and a perceived lag in AI innovation compared to surging tech peers. Investors are closely watching for an upcoming Supreme Court decision on tariffs and a potential rebound, with many anticipating strong future earnings to reverse the stock's recent divergence from overall market strength.

CorMedix, Inc. is a pharmaceutical and medical device company, which engages in the development and commercialization of therapeutic products for the prevention and treatment of diseases and conditions. The company was founded by Antony E. Pfaffle on July 28, 2006 and is headquartered in Berkeley Heights, NJ.

CorMedix Inc

CorMedix is trending after releasing preliminary Q4 results alongside cautious 2026 and 2027 revenue guidance for DefenCath, primarily due to anticipated changes in reimbursement. This news, coupled with recent insider share sales, has triggered a significant price decline, though many in the community perceive it as an overreaction and a buying opportunity for an undervalued stock. Despite strong recent financial performance, investors are actively debating management's long-term strategy and potential future dilution from acquisitions.

flyExclusive, Inc. engages in owning and operating jet aircraft for private jet passengers. It manages all aspects of the customer experience, in-house maintenance, repair, and overhaul services, including paint, interiors, and avionics capabilities. The company was founded by Thomas James Segrave, Jr. in 2015 and is headquartered in Kinston, NC.

flyExclusive Inc. - Ordinary Shares - Class A

FLYX is experiencing significant trading activity after announcing its role as an authorized Starlink Aviation dealer, integrating high-speed connectivity into its private jet services. The community is actively discussing the low float and potential for a short squeeze, with many anticipating a substantial move while others caution about profit-taking and volatility. This news positions the company at the forefront of in-flight innovation within the private aviation sector, driving widespread interest.

RAGE GUY (RAGE) is a cryptocurrency inspired by the Rage Guy meme, one of the earliest and most recognizable characters from internet rage comics. The project captures the cultural legacy of early meme history and brings it onto the blockchain in tokenized form. It is designed as a community-driven digital asset that celebrates internet culture, nostalgia, and the role memes play in shaping online communities.

Rage Guy

RAGE CRYPTO is currently trending, fueled by its exceptionally active community rallying behind the "OG meme" narrative of Rage Comics. The community is actively building out an ecosystem with tools like RageMaker and RageGames, expressing strong conviction that it represents a "meme reset" poised for significant leadership and growth in the crypto space.

Applied Digital Corp. is a technology company, which engages in the provision of development and operation of data centers which provide computing power. It operates through the Data Center Hosting Business and HPC Hosting Business segments. The Data Center Hosting Business segment provides energized infrastructure services to crypto mining customers. The HPC Hosting Business segment focuses on the designing, constructing, and operating data centers tailored to support high power density applications like HPC and AI. The company was founded by Wesley Carl Cummins and Jason Zhang in May 2001 and is headquartered in Dallas, TX.

Applied Digital Corporation

Applied Digital is a key trending stock following a strong earnings report that surpassed revenue and profitability estimates, fueled by rapid expansion in high-performance computing. Community discussion centers on the company's substantial data center pipeline, including advanced talks for new hyperscaler capacity, which could significantly boost contracted revenue and put pressure on short positions within the booming AI infrastructure sector.

iPower, Inc. engages in the online retail and supply of consumer home, garden, in-home farming, pet, and wellbeing products. It sells its brands such as Simple Deluxe, YSSOA, Zenhydro, Flourish, iPOWER, iFarm, FluffyDream, ScratchMe, and HealSmart through zenhydro.com, simpledeluxe.com, and various third-party online platforms. The company offers grow light systems, advanced heating, ventilation and air conditioning (HVAC) systems, water pumps, heaters, chillers and filters, nutrient and fertilizer delivery systems, and various growing media typically made from soil, rock wool or coconut fiber. It also provides home goods supplies including commercial fans, floor and wall fans, storage and shelving units, and chairs. The company was founded by Chenlong Tan and Allan Huang on April 11, 2018 and is headquartered in Rancho Cucamonga, CA.

iPower Inc

iPower Inc. is currently trending with high community interest, largely fueled by its extremely low public float after a recent capital structure change, leading to active speculation about a potential short squeeze. Investors are also discussing the company's strategic foray into digital assets, including initial purchases of Bitcoin and Ethereum, which is generating varied perspectives. This combination of tight market supply and a new crypto treasury strategy makes it a highly debated stock.

Ardelyx, Inc. is a biopharmaceutical company, which engages in the business of developing and commercializing biopharmaceutical products. The firm is also involved in developing a unique and innovative platform that enables the discovery of new biological mechanisms and pathways to develop potent and efficacious therapies that minimize the side effects and drug-drug interactions frequently encountered with traditional, systemically absorbed medicines. The company was founded by Dominique Charmot, Peter G. Schultz, and Jean M. Frechet in October 2007 and is headquartered in Waltham, MA.

Ardelyx Inc

ARDX is trending as investors digest the potential impact of Fosun Pharma's Wan Ti Le being included on China's National Reimbursement Drug List and analysts anticipate target price raises due to strong IBSRELA sales. The community is weighing potential revenue from China and speculating on milestone payments, while also discussing concerns about patent infringement and generic competition. Some investors express frustration with the stock's price movement despite positive developments, awaiting a CMS resolution.

MannKind Corp. is a biopharmaceutical company, which focuses on the development and commercialization of innovative therapeutic products and devices to address serious unmet medical needs for those living with endocrine and orphan lung diseases. Its products and pipeline include Afrezza, Pediatric Afrezza, V-Go, Tyvaso DPI, MNKD-101, MNKD-201, MNKD-301, and MNKD-501. The company was founded by Alfred E. Mann on February 14, 1991 and is headquartered in Danbury, CT.

Mannkind Corp

Mannkind Corp is trending following strong fourth quarter revenue guidance, highlighted by its record-setting performance, and recent FDA approval for pediatric use of its FUROSCIX On-body Infusor, alongside extended patent protection for the ReadyFlow Autoinjector. The community is actively discussing expectations for significant growth and potential M&A, particularly with partner United Therapeutics hitting new highs, though some investors express ongoing frustration with past leadership.

Aclarion, Inc. is a healthcare technology company, which engages in the provision of Magnetic Resonance Spectroscopy (MRS), and a proprietary biomarker to optimize clinical treatments. It utilizes Artificial Intelligence to assist in quality control processes that flag spectroscopy data indicative of a poor MRS study. It offers NOCISCAN Suite, a revolutionary software suite that works with existing high field Magnetic Resonance systems and Magnetic Resonance Spectroscopy pulse sequence packages using an optimized protocol to conduct MRS exams of lumbar discs. The company was founded by James C. Peacock, David S. Bradford, and Jeffrey Lotz in 2008 and is headquartered in Broomfield, CO.

Aclarion Inc

Aclarion Inc. (ACON) is trending after providing an upbeat corporate outlook, highlighting accelerating Nociscan AI platform adoption and a strong, debt-free balance sheet. The community is actively discussing the stock's exceptionally low float and substantial cash per share, igniting widespread speculation for a significant short squeeze. Investors are optimistic about its AI-driven healthcare solution and anticipate further upside as clinical trials progress.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

$QBTS What&#39;s the BIG... takeaway from D-Wave&#39;s First Scalable, On-Chip Cryogenic Control of Gate-Model Qubits ? 
 
It accelerates  D-Wave&#39;s Roadmap ! This milestone moves  
D-Wave(QBTS) closer to their goal of delivering a truly scalable, commercial-grade gate-model system, potentially sooner than competitors relying on less integrated approaches. 
 
D-Wave ALREADY has first-to-market advantage in annealing and optimization, which is 40% of the global quantum market 
 
Imagine D-Wave(QBTS) getting first to market advantage in gate-model ?   
 
If the above occurs, D-Wave(QBTS) has an excellent shot of becoming another NVDA, given that McKinsey estimates the global quantum market could reach $1T in about 10 years.

Domenico Caramia

StockTwits Web

D-Wave Quantum Inc

 What's the BIG... takeaway from D-Wave's First Scalable, On-Chip Cryogenic Control of Gate-Model Qubits ? 
 
It accelerates  D-Wave's Roadmap ! This milestone moves  
D-Wave(QBTS) closer to their goal of delivering a truly scalable, commercial-grade gate-model system, potentially sooner than competitors relying on less integrated approaches. 
 
D-Wave ALREADY has first-to-market advantage in annealing and optimization, which is 40% of the global quantum market 
 
Imagine D-Wave(QBTS) getting first to market advantage in gate-model ?   
 
If the above occurs, D-Wave(QBTS) has an excellent shot of becoming another NVDA, given that McKinsey estimates the global quantum market could reach $1T in about 10 years.

Socratic Thinker

@DeepValueStocks Forever it seams, the junction teams cited different use cases.  Annealing being good for salesman traveling. Junction junction good at functions.   
 
This development is a huge milestone for it crack&#39;s crackheads arguments into pieces. 
Should have today or will push the stock higher tomorrow. 
  
Deep pockets should roll in... Fintel can only show consumption of float and it&#39;s just best to be in it holding shares in the sellers side commanding price. 
 
Tech-wise, less wires means faster build times, better margin.  Lower cost machines that get the job done win. 
 
50 incoming

 Forever it seams, the junction teams cited different use cases.  Annealing being good for salesman traveling. Junction junction good at functions.   
 
This development is a huge milestone for it crack's crackheads arguments into pieces. 
Should have today or will push the stock higher tomorrow. 
  
Deep pockets should roll in... Fintel can only show consumption of float and it's just best to be in it holding shares in the sellers side commanding price. 
 
Tech-wise, less wires means faster build times, better margin.  Lower cost machines that get the job done win. 
 
50 incoming